Current Report Filing (8-k)

false 0001574774 0001574774 2021-01-28 2021-01-28

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 28, 2021

 

 

 

BioTelemetry, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Delaware		000-55039		46-2568498
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

 

1000 Cedar Hollow Road Malvern, Pennsylvania		19355
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: [phone]

Former name or former address, if changed since last report: Not Applicable

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		BEAT		NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

---

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(e)    On January 28, 2021, the compensation and talent development committee (the “Committee”) of the board of directors (the “Board”) of BioTelemetry, Inc., a Delaware corporation (the “Company”), approved amendments to the existing employment agreements with each of Heather Getz, Executive Vice President, Chief Financial and Administrative Officer, and Fred (Andy) Broadway III, President, BioTel Heart. The amendments increased the cash severance payments to which each of Ms. Getz and Mr. Broadway would be entitled if her or his employment is terminated by the Company without cause or by individual for good reason to (i) one and a half times her or his annual base salary as of the last day of active employment (increased from one times annual base salary) and (ii) one and a half times her or his target annual performance incentive bonus in effect at the time of her or his termination (increased from one times such bonus). In addition, the amendments increase Ms. Getz’s and Mr. Broadway’s right to continued coverage in the Company’s medical, dental and vision plans to eighteen months following the applicable date of the qualifying termination (increased from twelve months).

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

BioTelemetry, Inc.
By:		/s/ Heather C. Getz
Name:		Heather C. Getz
Title:		Executive Vice President, Chief Financial
		and Administrative Officer

Date: January 29, 2021